An Open-Label, Phase IB Study of R289, an IRAK1/4 Inhibitor, in Patients with Lower-Risk Myelodysplastic Syndrome (LR MDS) Who are Refractory/Resistant to Prior Therapies
Details
The study will be an open-label, Phase 1b study of R289 to determine tolerability and preliminary efficacy in patients with LR MDS who are relapsed, refractory/resistant, intolerant, or have inadequate response to prior therapies such as erythropoietin (EPO), thrombopoietin (TPO), luspatercept, or hypomethylating agents (HMAs) for MDS.
Eligibility
You can join if...
If you decide to participate in the study, some tests will be done to see if you are eligible. If the test results show that you meet the study requirements, then you will be able to start the study. If the test results show that you do not meet the study requirements, you will not be able to participate.